Joel McIntosh
Modoc County Office of Education(US)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Cancer-related Molecular Pathways, Protein Degradation and Inhibitors, Biochemical and Molecular Research, Microtubule and mitosis dynamics
Most-Cited Works
- → Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development(2014)291 cited
- → Structure-Based Drug Design of RN486, a Potent and Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis(2014)107 cited
- → Design and Synthesis of 4-Azaindoles as Inhibitors of p38 MAP Kinase(2003)95 cited
- → Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies(2024)87 cited
- → Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction(2014)83 cited
- → Discovery of 6-(2,4-Difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Pamapimod) and 6-(2,4-Difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as Orally Bioavailable and Highly Selective Inhibitors of p38α Mitogen-Activated Protein Kinase(2011)74 cited
- → Novel Inhibitors of the MDM2-p53 Interaction Featuring Hydrogen Bond Acceptors as Carboxylic Acid Isosteres(2014)54 cited
- → Discovery of AM-7209, a Potent and Selective 4-Amidobenzoic Acid Inhibitor of the MDM2–p53 Interaction(2014)47 cited
- → Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies(2020)46 cited
- → Finding the perfect spot for fluorine: Improving potency up to 40-fold during a rational fluorine scan of a Bruton’s Tyrosine Kinase (BTK) inhibitor scaffold(2014)33 cited